Crohn's disease (CD) is a chronic relapsing and remitting disease that can affect any segments of the gastrointestinal tract. More than 50% of patients with CD develop stricturing or penetrating complications within the first 10 years after diagnosis. Strictures can lead to intestinal obstruction, which is a common indication for surgery. Despite significant advances in the understanding of the pathogenesis of intestinal fibrostenosis, imaging and therapeutic armamentarium of CD, the risk of intestinal surgery remained significantly high. Endoscopic balloon dilation is a promising first-line alternative to surgery as it is less invasive and could preserve intestinal length. In this review, we will evaluate the literature on the mechanism of intestinal fibrosis, emerging imaging techniques, and management strategies for CD associated strictures.
Introduction
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with a relapsing and remitting course. The most common disease behavior at diagnosis is the inflammatory phenotype. Population-based cohort studies showed that up to 80% of patients with CD presented with inflammatory behavior, and 5% to 28% had stricturing disease. [1] [2] [3] [4] [5] [6] However, more than 50% of patients with CD develop stricturing or penetrating complications within the first 10 years after diagnosis. 7, 8 Stricturing CD results from intestinal fibrosis. It can occur at any time during the disease course and involve any intestinal segment, including the upper gastrointestinal tract. Two types of strictures in CD are identified: de novo and anastomotic. The commonest site of de novo strictures is the terminal ileum and the ileocolonic region. Postoperative recurrence of CD at the anastomosis occurs commonly after intestinal resection, particularly in patients with an ileocolonic anastomosis. 9 Patients with CD associated strictures are at risk for the development of intestinal obstruction, which is a common indication for surgery. 10 Although a systematic review and meta-analysis of population-based studies 11 reported that the risk of intestinal surgery among patients with IBD had decreased over the past six decades, the risk remained significantly high (16.3%, 33.3%, and 46.6% at 1, 5, and 10 years, respectively, after diagnosis of CD). Recent data from Australian cohorts reported similar rates of major abdominal surgery in CD patients at 5 and 10 years: 31.7% and 43.3%, respectively. 12, 13 Obstruction was the main indication for major abdominal surgery for CD in 24% to 40% of patients. 10, 13, 14 Approximately one-quarter of CD patients who have a first surgery also have a second, and the majority of these surgeries occur within 5 years of the first surgery. 15 In addition to the risk of postoperative morbidity and mortality, multiple surgeries predispose these patients to the risk of short bowel syndrome. Therefore, bowel-conserving procedures to avoid the risk of short bowel and surgical complications have been developed. Both endoscopic balloon dilation and surgical strictureplasty have undergone technological advances during the last two decades and hold promise of bowel preservation. In this article, we will review the current literature in the pathogenesis of intestinal fibrosis in CD; diagnosis; medical, endoscopic and surgical treatment of Crohn's strictures.
Mechanisms of fibrogenesis in Crohn's disease
Crohn's disease is characterized by chronic inflammation, ulcerations, and bowel injury leading to recurrent attempts of healing and closing the gap of ulcerations by disorganized deposition of extracellular matrix (ECM). Because of the transmural inflammation in CD, fibrosis can involve the full thickness of the bowel wall that includes the mucosa, submucosa, muscularis propria, and serosa layers. This will result in transmural thickening and stiffening with narrowing of the intestinal lumen leading to strictures and obstruction. The ECM is formed primarily of collagen subtypes I, III, and V deposited in the submucosal spaces as well in muscular layers by an increased number of activated fibroblasts and myofibroblasts. 16, 17 The latter are either derived from proliferation of resident mesenchymal cells, the induction of epithelial-to-mesenchymal or endothelial-to-mesenchymal transition or the recruitment and differentiation of bone marrow-derived fibrocytes. [18] [19] [20] [21] The most important driving force behind development of fibrosis is the cytokine transforming growth factor-β1 (TGFβ1) although other growth factors and cytokines such as interleukin (IL)-4, IL-5, IL-13, platelet-derived growth factor, connective tissue growth factor, basic fibroblast growth factor, insulin-like growth factor, and bone morphogenetic proteins are also involved in the pathophysiology of fibrosis.
22 TGFβ1 plays an important role in recruitment of fibroblasts, transdifferentiation to myofibroblasts, and stimulation of ECM secretion. 23, 24 TGFβ1 is an anti-inflammatory cytokine that supports wound healing but drives fibrosis. The extent of fibrosis depends on the balance between the production and degradation of ECM proteins. The deposited ECM are usually degraded by matrix metalloproteinases (MMPs) that can be induced by hepatocyte growth factor and inhibited by tissue inhibitor of metalloproteinases (TIMPs). In IBD with intestinal fibrosis, the balance between MMPs and TIMPs appears to be altered with downregulation of some MMPs and overexpression of TIMPs and thus favoring fibrogenesis and excessive deposition of ECM. [25] [26] [27] A simplified schematic illustration of the mechanism of intestinal fibrosis and stricture in CD is available in Figure S1 .
Diagnosis of strictures
The diagnosis of a stricture can be made by cross-sectional imaging or endoscopy. The advantages of endoscopic assessment of a stricture include the ability to obtain tissue samples for histological assessment and to provide therapy at the same setting. However, cross-sectional imaging is recommended to delineate the anatomy (number, location, length, morphology of strictures, and any associated complications that contraindicate endoscopic treatment) before endoscopic therapy. Several endoscopic scores are available for monitoring of endoscopic disease activity. The CD Endoscopic Index of Severity 28 and the Simple Endoscopic Score for CD 29 are validated and commonly used in clinical trials. Both incorporate "stenosis" as one of the variables in calculation of the total scores. Rutgeerts score 30 was developed to grade endoscopic postoperative recurrence in the neo-terminal ileum. Although not validated, it is the most commonly used score for assessing endoscopic disease activity after ileocecal resection. None of the scoring systems, however, have been validated with regard to differentiating the strictures into inflammatory and fibrotic types ( Table 1) .
Cross-sectional imaging is a pivotal tool in the management of IBD. Emerging imaging modalities have evolved over the last two decades that improve the diagnostic accuracy, and the ability to assess treatment responses and to detect complications. The imaging modalities commonly used to identify CD related strictures >5 apthous lesions with normal mucosa between the lesions, or skip areas of larger lesions or lesions confined to ileocolonic anastomosis i 3 Diffuse apthous ileitis with diffusely inflamed mucosa i 4 Diffuse inflammation with already larger ulcers, nodules, and / or narrowing include computed tomography enterography (CTE), magnetic resonance enterography (MRE), and bowel ultrasound (US). All three imaging techniques have high accuracy for evaluation of strictures affecting the small bowel or the colon: for CTE, sensitivity is 89% and specificity 99%; for MRE, sensitivity is 89% and specificity 94%; for US, sensitivity is 79% and specificity 92%. 31 Magnetic resonance imaging (MRI) and US do not require radiation and are more frequently used for assessment of patients with CD. Ultrasound has a lower sensitivity in detecting stenosis due to the difficulty visualizing the entire small bowel or colon. Overall, US seems to have a good accuracy for the detection of disease and assessment of disease activity localized in the terminal ileum and colon, except for the rectum and MRI has superior accuracy compared with US for the detection of lesions in the jejunum and more proximal ileum. 31 Strictures may be subdivided into inflammatory, fibrotic, and mixed types. Therefore, differentiating the composition of the strictures, namely, the relative proportions of inflammation and fibrosis, aids treatment decisions. Anti-inflammatory therapy is required for patients with strictures that have predominantly active inflammation, whereas predominantly fibrotic strictures are best managed by endoscopic or surgical treatment. Endoscopy with biopsies are unable to measure the amount of fibrosis existing in intestinal wall as inflammation and fibrosis in CD are transmural. This, however, can readily be assessed by cross-sectional imaging. Nonetheless, as most strictures have varying degrees of fibrosis and inflammation, detection and quantification of fibrosis deposition in the bowel wall by cross-sectional imaging remain challenging. A recent study on whether CTE can distinguish tissue inflammation from fibrosis suggested that small bowel stricture without inflammatory signs on CTE did not appear to be a useful predictor of tissue fibrosis (Fig. 1) . 32 Novel imaging techniques to detect CD bowel wall fibrosis include diffusion-weighted imaging (DWI) MR, dynamic contrast MR, magnetization transfer-MR, and ultrasound elastography. DWI is an additional MRI sequence that uses the motion of water molecules through tissues of differing cellular density to provide image contrast. Inflamed tissue has a higher cell density, and restricted diffusion, and therefore appears bright on DWI. 33 Dynamic contrast MRE works on examining contrast parameters in the delayed phase, thereby allowing differentiation between inflamed and fibrotic tissue, of which retention of contrast is longer in the latter. 34 MT-MR is a novel technique that quantifies the exchange of protons (magnetization transfer) between hydrogen nuclei in high-mobility environment, such as in free water molecules, and that in low-mobility environment, such as collagen in an aqueous physiological environment, thereby providing a more direct measurement of fibrosis. 35 Ultrasound elastography assesses fibrotic changes in a selected organ by measuring its deformability after the application of a force (strain). Significant correlation was demonstrated between the degree of intestinal fibrosis at histological examination and the quantitative measurement of intestinal stiffness at ultrasound elastography in patients with CD. 36, 37 These technologies are promising, but not ready for routine clinical practice yet.
There is growing interest in utilizing fecal markers to predict endoscopic recurrence after surgery for CD. 38, 39 In the first prospective, multicenter, randomized, controlled trial in the postoperative setting of CD, Wright et al. 38 showed that fecal calprotectin measurement had sufficient sensitivity and negative predictive values to monitor for CD recurrence after intestinal resection. After treatment for recurrence, the fecal calprotectin level can be used to monitor response with greater accuracy than C-reactive protein level or the Crohn's Disease Activity Index score.
Management of Crohn's disease associated strictures
Patients who present with symptoms and signs of intestinal obstruction due to suspected CD associated strictures should be hospitalized and managed by a multidisciplinary team comprising a gastroenterologist, colorectal surgeon, radiologist, pathologist, and dietitian. Conservative measures, including bowel rest, volume, and electrolytes replacement, should be instituted while waiting for evaluation with cross-sectional imaging to assess a possible stricture for number, location, length, the degree of inflammatory component, and accompanying features, such as abscess, phlegmon, or possible malignancy that may affect the management plan. Subsequent treatment options could be grouped into medical, endoscopic, and surgical strategies.
Medical treatment. If cross-sectional imaging confirms presence of inflammatory component in the stricture, corticosteroid could be introduced that might decrease bowel wall edema with subsequent reduction of bowel wall thickness and therefore relief of the obstructive symptoms. 40 At present, there are no approved or effective medical therapies targeting intestinal fibrosis. 41 Although improved management of CD inflammation by anti-tumor necrosis factor (TNF)-α therapy appears to reduce the rate of stricture development 42 especially if started early, 43 there were concerns about possible promotion of stricture formation from rapid healing of ulcers after anti-TNF therapy. 44, 45 However, data from the Crohn's Therapy, Resource, Evaluation, and Assessment Tool (TREAT) registry 46 and the A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen (ACCENT I) trial 47 did not show an increased risk of obstruction in patients with or without intestinal stricture at baseline. In fact, more recent data demonstrated that adalimumab was an efficient treatment in symptomatic small bowel stricture associated with CD. Bouhnik and colleagues performed a multicenter, prospective, observational cohort study in patients with CD and symptomatic small bowel stricture. 48 The primary endpoint, defined as success at week 24, was achieved in 64% of patients and was prolonged in nearly half of them till the end of follow up (3.8 years). More than half of the patients were free of surgery 4 years after treatment initiation.
Evidence suggests that inflammation is necessary for establishing fibrosis but subsequently plays a minor role in its progression. Mechanisms that regulate fibrosis, therefore, appear to be distinct from those regulating inflammation, 49, 50 and this might explain why strictures may present years after remission of active inflammation. 51 Intestinal fibrosis has been considered as an irreversible process necessitating endoscopic or surgical intervention; however, specific antifibrotic medical approaches may become available. Most of the information and data on fibrosis treatment come from studies on hepatic and pulmonary fibrosis with scarce studies in IBD. Many drugs developed for treatment of pulmonary fibrosis may be potential candidates for the treatment of intestinal fibrosis. Pirfenidone (a growth factor inhibitor), 52, 53 SD-208 (a TGF-βR1 signaling blocker), 24 Nintedanib (a kinase inhibitor that acts on vascular endothelial fibroblast growth factor receptors), 53 Integrin αvβ6 (activates latent TGFβ) inhibitor, 54 Simtuzumab (a monoclonal antibody to LOXL2) in combination with Relaxin (an inhibitor of myofibroblast contraction), 55 rapamycin and its analogs, sirolimus and everolimus (through their immunosuppressive and anti-fibrotic action), 56, 57 serotonin (inducer of myofibroblast activation) receptor inhibitors, 58, 59 and Rho kinase (activator of mesenchymal cells) inhibitor 60 have shown some success in the treatment of pulmonary fibrosis in humans and in experimental intestinal fibrosis in animal models. The real clinical effectiveness of these agents in IBD remains to be defined in human trials. Such trials have not been initiated yet and may be hampered by the fact that intestinal fibrosis in IBD is a long process and therefore any clinical benefit of these drugs may not be demonstrated until many years of treatment.
In summary, the initial management of patients with intestinal strictures and obstruction still relies on bowel rest and steroids aiming at decreasing any possible inflammation and edema coexisting with fibrosis. Anti-TNF is an efficient treatment in symptomatic small bowel stricture associated with CD. Patients whose strictures fail to respond to medical treatment require endoscopic or surgical intervention.
Endoscopic treatment. There are a few modalities for endoscopic treatment of Crohn's stricture. This entails endoscopic balloon dilation (EBD), intralesion injection of corticosteroids or anti-TNF agents, and metallic biodegradable or removable stents.
Endoscopic balloon dilation. Endoscopic balloon dilation seems to be a promising first-line alternative for treatment of stricturing CD because it is minimally invasive and can preserve bowel length. Through-the-scope radial expanding balloon dilators are commonly used to reach and pneumatically dilate strictures that are usually located in the colon or ileocolon. The balloon dilators may be passed through the endoscope with or without wire guidance. Different balloon calibers and lengths are available. Some allow for sequential expansion to multiple diameters, while others have one fixed diameter. For a detailed description of the different models of balloon dilators, we refer the reader elsewhere. 61 Although many studies have been published that described the technique of EBD, they were small and heterogeneous with regard to stricture lengths, balloon diameters, duration of balloon inflation, frequency of follow up dilations and so forth, making comparison across the studies difficult in systematic reviews. 62 The heterogeneity in the practice is also reflected in a recent web-based survey to IBD specialists on endoscopic management of CD-associated strictures. 63 There were differences in management approach based on background of the operator, experience level, and practice setting. For example, surgeons more frequently chose surgical resection/strictureplasty as a first-line treatment option for de novo ileocecal strictures compared with gastroenterologists. Experienced operator (who performed more than 30 dilations annually) would dilate active inflammatory strictures more often, use larger balloons, and set a longer maximum stricture length regarded as appropriate for EBD. 63 Endoscopic balloon dilation is indicated when strictures are accessible to endoscopes (these include colonoscopy, enteroscopy, and gastroscopy), ≤5 cm in length, 64 non-angulated, with sizeable lumen to admit balloon dilators 62 and without contraindications such as presence of fistula, abscess, or malignancy. Previous guidelines recommended EBD for short strictures ≤4 cm in length. 65 In a recent pooled analysis of 1463 patients with CD who underwent 3213 EBD procedures (of which >98% were ileal strictures and 60% were anastomotic), 64 Bettenworth et al. found that a stricture length of ≤5 cm was associated with a longer surgery-free interval. The rate of technical success of EBD (defined as the ability to pass a colonoscope through the nontraversable stricture after dilation or correct stent placement) was 89.1%. 64 A greater maximum dilation diameter and de novo strictures were associated with a higher likelihood of technical success. The clinical efficacy (defined as relief of clinical symptoms of bowel obstruction) was 80.8%. The complication rate, defined as bleeding, perforation, or hospitalization, was 2.8% per procedure. During a median follow-up period of 24 months, EBD was able to postpone surgical intervention in about 67% of patients. Interestingly, the presence of active disease at the site of the stricture, the presence of a naïve versus an anastomotic stricture, or any technical features, such as maximal balloon diameter or dilation time, did not affect short-term (clinical efficacy) or long-term outcomes (symptom recurrence or the need for repeat endoscopic dilation) or rates of complications. 64 With regard to EBD technique, the maximum balloon diameter recorded in the studies ranged from 15 to 25 mm, but an increased caliber of dilation neither resulted in increased rates of clinical efficacy nor reduced the need for redilation or surgery. 64 In a recent retrospective review of patients with symptomatic CD-related strictures undergoing EBD, Reutemann and colleagues found that although there was no difference in the risk of future surgery between maximum EBD sizes of 14 to 15 mm and 16 to 18 mm, those reaching 16 to 18 mm exhibited a longer interval between subsequent dilations (mean 240 ± 136.7 vs 456 ± 357.3 days, respectively, P = 0.023). 66 Moreover, dilating strictures up to 25 mm had a higher than average complication rates. Balloon diameter of 20 mm seems to be the commonest and most effective size limit. 62 There are no data to support the best duration of dilation. The reported duration for the dilation ranged from 1 to 5 min. A few studies dilated for 1 min, but the majority of studies dilated for 2 min.
Repetitive dilations of the same stricture are frequently performed in clinical practice. 63 Retrospective data suggested that short-term and long-term outcomes, as well as complication rates, remain the same compared with the first dilation. 67, 68 Furthermore, the use of combination medical therapy with an immunomodulator and anti-TNF decreased the need for repeat dilation of anastomotic strictures. 69 Few articles focused on EBD in the management of CD related strictures in the upper gastrointestinal (GI) tract. 70 Bettenworth et al. established that the technical and complication rates were comparable with those of ileocolonic strictures, but stricture location in the duodenum had an approximately five times increased hazard for shorter time to surgery compared with that in the jejunum/ileum or colon. 64 Two recent studies on dilation of de novo upper gastrointestinal strictures associated with CD showed a technical success rate of 93% and an overall complication rate of 3-4%. EBD delayed the need for surgery in about 56-66% of patients over a median follow-up of 23 to 24 months. 71, 72 Similarly, emerging data from retrospective studies, [73] [74] [75] [76] [77] [78] [79] revealed that double-balloon endoscopy-assisted EBD provided a reasonable technical success rate (72% to 100%), short-term efficacy (about 70%), and safety (complication rate of 0% to 10%) in patients with small intestinal CD-associated de novo strictures. Of note, the first prospective study on EBD using balloon-assisted enteroscopy for small bowel strictures in CD 80 demonstrated a technical success rate of 94%, a short-term clinical efficacy of 70%, and a complication (bleeding) rate of 5%.
Intralesional injection of corticosteroid and infliximab.
There is limited and contradictory evidence from two randomized controlled trials 81, 82 on the use of endoscopic injection of corticosteroids into strictures post dilation. While intralesional corticosteroid injection after EBD in the pediatric CD cohort with strictures reduced the need for both redilation and surgery, 82 intra-stricture triamcinolone injection after EBD in adult Crohn's ileocolonic anastomotic strictures did not decrease the time to redilation and in fact a trend toward a worse outcome was reported. 81 Therefore, corticosteroid injection after EBD cannot be recommended currently. There were some case reports 83, 84 showing success of injection of anti-TNF agents into patients with CD-associated strictures; combining EBD of strictures with serial intralesional injection of infliximab in small bowel CD was also successful in reducing inflammation. 85 Larger prospective studies are required before intralesional injection of anti-TNF could be recommended in clinical practice.
Stenting. The effectiveness of metallic stents in malignant strictures of the gastrointestinal tract has allowed extension of their use in CD related strictures. Two types of stents are available: self-expanding metal stents and biodegradable stents. However, the literature regarding the efficacy and safety of those stents in the treatment of strictures in CD is limited to case reports and retrospective review. Available data suggested that placement of fullycovered self-expanding metal stents in CD maintained over a period of 4 weeks was a safe and effective treatment for strictures refractory to EBD. 86 The technical success rate was 92%, and the efficacy was 65% after a mean follow-up time of 60 weeks. The lack of longterm efficacy and safety concerns of stent placement, such as adherence of the stent to the mucus membrane of the bowel, perforation, and spontaneous distal migration of the stent, may limit the applicability. The data on the use of biodegradable stents in CD patients are scarce with case series 87 and case reports 88, 89 only, so no definitive conclusion could be made.
Endoscopic needle knife stricturotomy. A novel, promising technique to treat strictures in patients with IBD, called endoscopic needle knife stricturotomy (NKSt), was recently reported. 90 A total of 127 strictures in 85 patients (50 with UC and 35 with CD) were treated with endoscopic NKSt, and each patient received a median of 2.0 treatments. The strictures included primary strictures (CD stricture, fecal diversion-related stricture, and pouch inlet stricture) and secondary strictures (anastomotic strictures, inlet or outlet of CD stricturoplasty site, ileal pouch anastomosis, and nipple valve of the Kock pouch). The immediate success with passage of the scope through the stricture after NKSt was 100%. Fifteen percent of patients required stricture-related surgeries after a median follow up of 0.9 years. The complication (bleeding and perforation) rate was 3.7%.
In summary, EBD is an effective first-line therapy for CD associated strictures. The technical success rate, clinical efficacy, and complication rate are 89%, 81%, and 2.8%, respectively. The goal is to reach a size of 20 mm with dilation. Over a 24-month period, it can delay surgery in about two-thirds of patients. Combination therapy (immunomodulator and anti-TNF) may decrease the need for repeat dilation of anastomotic strictures. Intralesional injection of corticosteroid and anti-TNF could not be recommended currently.
Surgery. Despite the best therapy, up to 66% 91, 92 of patients with stricturing CD fail medical therapy and 40% 64 fail endoscopic dilation and thus will require surgery. Preserving bowel length is essential to the treatment of these patients. Two common surgical procedures are recognized in the management of CD stricture: strictureplasty and resection.
Strictureplasty. In general, strictureplasties are categorized into conventional versus nonconventional procedures. The conventional strictureplasties, including the Heineke-Mikulicz 93 and Finney strictureplasties, 94 remain the most commonly used techniques. 95 In Heineke-Mikulicz strictureplasty (suitable for 5-to 10-cm strictures) (Fig. 2) , a single longitudinal incision is made over the stricture and extended by about 2 cm both proximal and distal to the thickened bowel segment. The enterotomy is then closed transversely. In Finney strictureplasty (suitable for 10-to 25-cm strictures) (Fig. 3) , the strictured segment is folded into a "U"-shape, and an enterotomy is made on the antimesenteric border. The opposed walls of the bowel are sutured together to create a blind pouch. Nonconventional strictureplasties, such as Michelassi strictureplasty 96 ( Fig. 4) and widening ileocolic strictureplasty, have emerged over the past decades to facilitate conservation of bowel length in patients with longer and atypical stricture presentations. In a systematic review and meta-analysis, Campbell et al. 97 reported that the nonconventional strictureplasty techniques were non-inferior to the conventional strictureplasty procedures with respect to immediate and long-term complication rates. The overall rate of early complications such as small-bowel obstruction, sepsis, reoperation, and early postoperative gastrointestinal bleed had been reported at 13%, whereas the rate of late complication was about 26%. Table 2 presents the indications and contraindications to strictureplasty in CD related strictures 98, 99 . Strictureplasty is generally not recommended for Crohn's colonic stricture due to the potential presence of a malignancy. Patients with CD are also at increased risk of development of small bowel cancer; the absolute risk, however, remains low. In a retrospective review of IBD patients without known dysplasia or cancer in the colorectal stricture at the time of resection, cancer or dysplasia was observed in 3.5% of the overall IBD population. 100 Cancer was observed in 0.8% of CD patients and 5% of UC patients. Any small bowel or colorectal stricture should therefore be extensively 98, 99 Indications 1. Fibrotic strictures within diffuse involvement of the small bowel 2. Previous extensive (>100 cm) small bowel resections 3. Short bowel syndrome 4. Recurrent strictures within 12 months of previous surgery 5. Strictures at previous anastomotic sites, particularly ileorectal or ileocolonic 6. Strictures without phlegmon or septic fistula 7. Duodenal strictures, particularly in the retroperitoneal segment Contraindications 1. Perforation of the small bowel, with or without peritonitis 2. Preoperative malnutrition (serum albumin <2.0 g/dL) 3. Fistula or phlegmonous inflammation at intended strictureplasty site 4. Bleeding from planned strictureplasty site 5. Suspicion for carcinoma 6. Likelihood of tension on closure of strictureplasty 7. Intended strictureplasty site next to segment requiring resection assessed with multiple biopsies during endoscopy to ensure the absence of malignancy, although we need to be cautious that negative endoscopic biopsy specimens of stricture do not entirely rule out the presence of dysplasia or cancer in both CD and UC. Patients with strictures of the colon that cannot be adequately surveyed endoscopically should be considered for resection.
Which therapy to choose-endoscopic balloon dilation, strictureplasty, or resection?
Before making a decision on the most appropriate therapy for CDassociated stricture, the anatomy of the stricture (number, location, stricture length, and angulation) as well as accompanying complications (such as abscess, phlegmon, dysplasia, or malignancy) should be assessed with a combination of endoscopy and crosssectional imaging. The patient's preference should also be taken into consideration. The three options are not mutually exclusive and combination of, for example, strictureplasty and resection, may be required to achieve the best outcome for patients.
In general, strictures that are accessible to endoscopes, ≤5 cm in length, non-angulated, with sizeable lumen to admit balloon dilators, are ideal for EBD. The treatment of choice for colonic stricture is EBD or segmental resection. Strictureplasty may be best applied to strictures of the second and third part of duodenum. Both strictureplasty and resection show similar short-term and long-term results for strictures at the jejunum and ileum, including ileocolonic recurrence. When there are multiple jejunoileal strictures, the surgical approach is based on a combination of small bowel resections and strictureplasties. 101 Michelassi strictureplasty is the preferred technique for the treatment of long stenotic segments or multiple and adjacent strictures. Strictures in the antrum and duodenal bulb are most commonly treated by a distal gastrectomy with Roux-en-Y bypass. 101 A summary of the management options for CD associated stricture is presented in Table 3 . A flow chart guiding the treatment decision is shown in Figure 1 .
Conclusion
We have a better understanding of the pathogenesis of intestinal fibrosis in CD. Emerging imaging modalities are available to improve the diagnosis and characterization of CD strictures. Accumulated evidence supports the use of endoscopic balloon dilation as first-line therapy for CD stricture. Antifibrotic therapy, endoscopic stenting, and stricturotomy are promising strategies to improve the outcome of CD associated strictures.
